MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO

MBX Biosciences, Inc.

CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
John Smither appointed Interim CFO effective March 16, 2026; base salary $325k, target bonus 40%, $25k sign-on.
Lease entered for 13,642 sqft office/lab in Burlington, MA; aggregate base rent ~$3.4M over 4-year term.
Departure not due to dispute; search for permanent CFO underway.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MBX Biosciences, Inc. entered into Lease Agreement with 5 Burlington Woods, LLC valued at approximately $3.4 million (effective 2026-02-24).

Action: entry
Agreement: lease
Counterparty: 5 Burlington Woods, LLC
Value: approximately $3.4 million
Effective: 2026-02-24

Exact text from the filing

On February 24, 2026, MBX Biosciences, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement”) with 5 Burlington Woods, LLC ("5 Burlington Woods") to lease approximately 13,642 square feet of new office and laboratory space in Burlington, MA

View on SEC.gov

Browse all material agreements →

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-079286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.